Open AccessIn silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor
Author(s) -
ArieyBonnet Jeremy,
Carrasco Kendall,
Le Grand Marion,
Hoffer Laurent,
Betzi Stéphane,
Feracci Mikael,
Tsvetkov Philipp,
Devred Francois,
Collette Yves,
Morelli Xavier,
Ballester Pedro,
Pasquier Eddy
Publication year - 2020
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12810
Subject(s) - mebendazole , in silico , mapk14 , kinase , biology , kinome , drug discovery , pharmacology , biochemistry , protein kinase a , cyclin dependent kinase 2 , gene , ecology
Drug polypharmacology was explored in silico to identify novel molecular targets of antihelminthic drug mebendazole, currently repurposed for the treatment of brain cancers. By combining transcriptomic analysis, molecular docking, and functional assays (biophysical, biochemical, and cellular), we validated MAPK14 as a critical target of mebendazole and a key player in glioblastoma progression.